Santini Giuseppe, Mores Nadia, Penas Andreu, Capuano Rosamaria, Mondino Chiara, Trové Andrea, Macagno Francesco, Zini Gina, Cattani Paola, Martinelli Eugenio, Motta Andrea, Macis Giuseppe, Ciabattoni Giovanni, Montuschi Paolo
Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, Italy.
Curr Top Med Chem. 2016;16(14):1610-30. doi: 10.2174/1568026616666151223113540.
Breathomics, the multidimensional molecular analysis of exhaled breath, includes analysis of exhaled breath with gas-chromatography/mass spectrometry (GC/MS) and electronic noses (e-noses), and metabolomics of exhaled breath condensate (EBC), a non-invasive technique which provides information on the composition of airway lining fluid, generally by high-resolution nuclear magnetic resonance (NMR) spectroscopy or MS methods. Metabolomics is the identification and quantification of small molecular weight metabolites in a biofluid. Specific profiles of volatile compounds in exhaled breath and metabolites in EBC (breathprints) are potentially useful surrogate markers of inflammatory respiratory diseases. Electronic noses (e-noses) are artificial sensor systems, usually consisting of chemical cross-reactive sensor arrays for characterization of patterns of breath volatile compounds, and algorithms for breathprints classification. E-noses are handheld, portable, and provide real-time data. E-nose breathprints can reflect respiratory inflammation. E-noses and NMR-based metabolomics of EBC can distinguish patients with respiratory diseases such as asthma, COPD, and lung cancer, or diseases with a clinically relevant respiratory component including cystic fibrosis and primary ciliary dyskinesia, and healthy individuals. Breathomics has also been reported to identify patients affected by different types of respiratory diseases. Patterns of breath volatile compounds detected by e-nose and EBC metabolic profiles have been associated with asthma phenotypes. In combination with other -omics platforms, breathomics might provide a molecular approach to respiratory disease phenotyping and a molecular basis to tailored pharmacotherapeutic strategies. Breathomics might also contribute to identify new surrogate markers of respiratory inflammation, thus, facilitating drug discovery. Validation in newly recruited, prospective independent cohorts is essential for development of e-nose and EBC NMRbased metabolomics techniques.
呼吸组学是对呼出气体进行多维度分子分析,包括利用气相色谱/质谱联用仪(GC/MS)和电子鼻对呼出气体进行分析,以及对呼出气冷凝液(EBC)进行代谢组学分析。EBC分析是一种非侵入性技术,通常通过高分辨率核磁共振(NMR)光谱法或质谱法来提供气道衬液成分的信息。代谢组学是对生物流体中小分子量代谢物进行鉴定和定量。呼出气体中挥发性化合物和EBC中代谢物的特定谱图(呼吸印记)可能是炎症性呼吸系统疾病的潜在有用替代标志物。电子鼻是人工传感系统,通常由用于表征呼吸挥发性化合物模式的化学交叉反应传感器阵列和用于呼吸印记分类的算法组成。电子鼻便于携带,可提供实时数据。电子鼻呼吸印记能够反映呼吸道炎症。电子鼻和基于NMR的EBC代谢组学能够区分患有呼吸系统疾病(如哮喘、慢性阻塞性肺疾病和肺癌)或具有临床相关呼吸成分的疾病(包括囊性纤维化和原发性纤毛运动障碍)的患者与健康个体。据报道,呼吸组学还可识别受不同类型呼吸系统疾病影响的患者。电子鼻检测到的呼吸挥发性化合物模式和EBC代谢谱与哮喘表型相关。与其他组学平台相结合,呼吸组学可能为呼吸系统疾病表型分析提供分子方法,并为量身定制的药物治疗策略提供分子基础。呼吸组学还可能有助于识别呼吸道炎症的新替代标志物,从而促进药物发现。在新招募的前瞻性独立队列中进行验证对于电子鼻和基于EBC NMR的代谢组学技术的开发至关重要。